secukinumab (Cosentyx)

following a full submission

secukinumab (Cosentyx®) is accepted for restricted use within NHS Scotland.

Indication under review: treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

SMC restriction: for patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments.
Secukinumab was superior to placebo and to a tumour necrosis factor (TNF) antagonist for improving symptoms of patients with moderate to severe plaque psoriasis.
This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost effectiveness of secukinumab. It is contingent upon the continuing availability of the Patient Access Scheme in NHS Scotland or a list price that is equivalent or lower.